LY3214996 Plus Abemaciclib in Recurrent Glioblastoma Patients

Glioblastoma Clinical Trial

Official title:

A Phase 0/2 Study of LY3214996 (ERK Inhibitor) in Combination With Abemaciclib (CDK4 and 6 Inhibitor) in Recurrent Glioblastoma Participants Scheduled for Resection to Evaluate Central Nervous System (CNS) Penetration

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04391595
• Other study ID #: 2019-07
• Status: Recruiting
• Phase: Early Phase 1
• Start date: July 8, 2020
• Est. completion date: February 2025

Study information

• Verified date: March 2024
• Source: St. Joseph's Hospital and Medical Center, Phoenix
• Contact: Phase 0 Navigator
• Phone: 602-406-8605
• Email: research[@]ivybraintumorcenter.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This trial is an open-label, multicenter, Phase 0/2 trial that will enroll up to 50 participants with recurrent glioblastoma which are schedule for resection. In the lead-in cohort, a total of 10 participants will be enrolled into the proposed phase 0 clinical trial. Participants will be administered LY3214996 plus Abemaciclib prior to surgical resection of their tumor. If positive PK results are demonstrated in ≥50% of Phase 0 participants and at least 5 participants are enrolled into Phase 2, up to approximately 40 additional participants will be enrolled in the dose expansion cohort in order to achieve a total of 25 participants enrolled into Phase 2 (lead-in cohort + dose expansion).

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. completion date: February 2025
• Est. primary completion date: December 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Prior resection of histologically diagnosed WHO Grade IV glioma defined as glioma participants who have progressed on or following standard (Stupp regimen) therapy, which included maximal surgical resection, temozolomide, and fractionated radiotherapy.

2. Recurrence must be confirmed by diagnostic biopsy with local pathology review or contrast-enhanced MRI.

3. Participants must have measurable disease preoperatively, defined as at least 1 contrast-enhancing lesion, with 2 perpendicular measurements of at least 1 cm, as per RANO criteria.

4. Sufficient archival tissue available to confirm eligibility.

5. For gliomas, archival tissue must demonstrate: (a) RB positivity (=20%) on immunohistochemistry (IHC); or, no RB mutations on next-generation sequencing (NGS), (b) Chromosomal loss of CDKN2A/B/C; or, CDK4/6 amplification on array CGH or NGS, (c) pERK positivity (>30%) on IHC.

6. Ability to understand and the willingness to sign a written informed consent document (personally or by the legally authorized representative, if applicable).

7. Participant has voluntarily agreed to participate by giving written informed consent (personally or via legally authorized representative(s), and assent if applicable). Written informed consent for the protocol must be obtained prior to any screening procedures. If consent cannot be expressed in writing, it must be formally documented and witnessed, ideally via an independent trusted witness.

8. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other procedures.

9. Age =18 at time of consent

10. Have a performance status (PS) =2 on the Eastern Cooperative Oncology (Group (ECOG) scale (Oken et al. 1982)

11. Ability to swallow oral medications.

12. Participant has adequate bone marrow and organ function as defined by the following laboratory values (as assessed by the local laboratory for eligibility):

Adequate bone marrow function:

• absolute neutrophil count =1,000/mcL
• platelets (at time of surgery) =100,000/mcL
• hemoglobin =8.0 g/dL Participants may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.

Adequate hepatic function:

• total bilirubin =1.5 X ULN Participants with Gilbert's syndrome with a total bilirubin =2.0 times ULN and direct bilirubin within normal limits are permitted.
• AST(SGOT) =3 X institutional ULN
• ALT(SGPT) =3 X institutional ULN

13. Confirmed negative serum pregnancy test (ß-hCG) before starting study treatment or participant or participant who is no longer of childbearing potential due to surgical, chemical, or natural menopause.

14. For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 6 months after the end of treatment administration.

15. For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner and for an additional 6 months after the end of treatment administration.

16. Agreement to adhere to Lifestyle Considerations throughout study duration

17. Participants who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events [CTCAE] Grade =1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to Day 1. A washout period of at least 21 days is required between last chemotherapy dose and Day 1 (provided the patient did not receive radiotherapy).

18. Participants who received radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and Day 1.

Exclusion Criteria:

1. Current use of coumarin-derived anticoagulant for treatment, prophylaxis or otherwise. Therapy with heparin, low molecular weight heparin (LMWH) or fondaparinux is allowed.

2. Pregnancy or lactation.

3. Known allergic reactions to components of the abemaciclib or LY3214996.

4. Active infection or fever >38.5°C requiring systemic antibiotic, antifungal or antiviral therapy within 4 weeks of Day 1.

5. Known to have active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis.

6. Known active systemic bacterial infection (requiring intravenous [IV] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C [for example, hepatitis B surface antigen positive]. Screening is not required for enrollment.

7. Have history of central or branch retinal artery or venous occlusion with significant vision loss or other retinal diseases that cause current visual impairment or would likely cause visual impairment over the time period of the study.

8. Participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study (for example, interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment [e.g. estimated creatinine clearance <30ml/min], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).

9. Prior therapy with any CDK4/6 inhibitor or any ERK1/2 inhibitor. Prior therapy is defined as a therapeutic dosing.

10. Treatment with another investigational drug or other intervention within 30 days prior to enrollment or within 5 half-lives of the investigational product, whichever is longer.

11. Have a mean QT interval corrected for heart rate (QTc) of =470 milliseconds on screening electrocardiogram (ECG) as calculated using the Bazett's formula.

12. The patient has a personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest.

Related Conditions & MeSH terms

• GBM
• Glioblastoma
• Glioma

Intervention

Drug:
• Abemaciclib
100 mg of Abemaciclib BID for 11 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.
• LY3214996
400 mg of LY3214996 daily for 6 doses over 5.5 days prior to surgical resection. Participants with tumors demonstrating PK-response in Phase 0 will continue treatment with recommended Phase 2 dose (RP2D) continuously in 21d cycles after surgery.

Locations

Country	Name	City	State
United States	Chandler Regional Medical Center	Chandler	Arizona
United States	St. Joseph's Hospital and Medical Center	Phoenix	Arizona
United States	HonorHealth Scottsdale Osborn Medical Center	Scottsdale	Arizona

Sponsors (4)

Lead Sponsor	Collaborator
Nader Sanai	Barrow Neurological Institute, Eli Lilly and Company, Ivy Brain Tumor Center

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 0: Pharmacokinetic analysis of tumor tissue	Total and Unbound LY3214996 and Abemaciclib (and related M2 and M20 metabolites) concentration in enhancing and non-enhancing tumor tissue	8 hour
Primary	Phase 0: Pharmacokinetic analysis of cerebrospinal fluid (CSF)	Total and Unbound LY3214996 and Abemaciclib (and related M2 and M20 metabolites) concentration in CSF	8 hour
Primary	Pharmacokinetic analysis of plasma	Total and Unbound LY3214996 and Abemaciclib (and related M2 and M20 metabolites) concentration in plasma	Day 6 at 0, 0.5, 1, 2, 4, 6, 8, 12 and 24 hours post dose
Primary	Phase 2: Progression-free survival	Phase 2: 6-month progression-free survival (PFS6) rate measured from time of surgery to date of recurrence	up to 60 months
Secondary	Phase 0: PD Analysis	Phase 0: percentage of pRSK+, pERK+, pRB+, pFOXM1, MIB-1+ and Cleaved Caspase 3+ cells from the surgical tissue will be quantified and compared to baseline archival tissue.	Intraoperatively
Secondary	Number of Adverse Events	Number of Adverse Events	up to 30 days after the last study dose
Secondary	Incidence of drug-related toxicity	Drug-related toxicity	up to 30 days after the last study dose
Secondary	Incidence of treatment-emergent adverse events	Treatment-emergent adverse events	up to 30 days after the last study dose
Secondary	Deaths	Deaths	up to 60 months
Secondary	Incidence of clinical laboratory abnormalities per CTCAE	Clinical laboratory abnormalities per CTCAE	up to 30 days after the last study dose

External Links

•   Ivy Brain Tumor Center Website